Idiopathic pleuroparenchymal fibroelastosis: A review of the previous literature and current knowledge
- PMID: 39693846
- DOI: 10.1016/j.resinv.2024.12.009
Idiopathic pleuroparenchymal fibroelastosis: A review of the previous literature and current knowledge
Abstract
Idiopathic pleuroparenchymal fibroelastosis (iPPFE) is characterized by upper lobe-dominant fibrosis involving the pleura and subpleural lung parenchyma. Pathologically, it is characterized by parenchymal intra-alveolar fibrosis with marked deposition of elastic fibers and dense thickening of the visceral pleura. Since iPPFE was categorized as a rare idiopathic interstitial pneumonia (IIP) by the America Thoracic Society/European Respiratory Society, several studies have been conducted, revealing an overall picture of iPPFE in terms of epidemiology, clinical manifestations, and mortality, in addition to its radiological and histological characteristics. Subsequently, several clinical diagnostic criteria that were not necessary for pathological analyses were proposed. Further, the underlying diseases responsible for secondary PPFE and PPFE-like lesions and their clinical implications were delineated. Typically, patients with iPPFE exhibit lean body stature together with platythorax, as well as relatively severe impairment of pulmonary function. In addition to upper-lobe PPFE lesions, lower-lobe interstitial lung disease (ILD) is commonly observed in patients with iPPFE, with the usual interstitial pneumonia pattern being most frequent. These distinct features of iPPFE were mostly associated with mortality, resulting in a poor prognosis relative to fibrotic ILD. Despite increased knowledge regarding the clinical characteristics of iPPFE, no effective therapy has been established other than lung transplantation. The efficacy of antifibrotic therapy, nutrition intervention, and pulmonary rehabilitation has not been determined. This article reviews previous studies and discusses the etiology, clinical manifestations, mortality risk, and treatment of iPPFE.
Keywords: Clinical manifestation; Idiopathic pleuroparenchymal fibroelastosis; Mortality risk; PPFE-Like lesion.
Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest The author has no conflict of interest.
Similar articles
-
Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis.Respir Med. 2019 Jul-Aug;154:122-126. doi: 10.1016/j.rmed.2019.06.018. Epub 2019 Jun 20. Respir Med. 2019. PMID: 31238182
-
The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.Histol Histopathol. 2021 Mar;36(3):291-303. doi: 10.14670/HH-18-289. Epub 2020 Dec 14. Histol Histopathol. 2021. PMID: 33315234 Review.
-
Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study.Respir Med. 2017 Dec;133:1-5. doi: 10.1016/j.rmed.2017.11.003. Epub 2017 Nov 6. Respir Med. 2017. PMID: 29173442
-
Whole-lung pathology of pleuroparenchymal fibroelastosis (PPFE) in an explanted lung: Significance of elastic fiber-rich, non-specific interstitial pneumonia-like change in chemotherapy-related PPFE.Pathol Int. 2019 Sep;69(9):547-555. doi: 10.1111/pin.12833. Epub 2019 Jul 10. Pathol Int. 2019. PMID: 31290582
-
Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal.Respir Investig. 2019 Jul;57(4):312-320. doi: 10.1016/j.resinv.2019.02.007. Epub 2019 Apr 10. Respir Investig. 2019. PMID: 30981683 Review.
Cited by
-
Positive Effects of Nutritional Education in a Patient With Pleuroparenchymal Fibroelastosis.Cureus. 2025 Feb 13;17(2):e78976. doi: 10.7759/cureus.78976. eCollection 2025 Feb. Cureus. 2025. PMID: 40091992 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources